
Affiliations:

1. Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis (TN), USA.
2. Department of Oncology, St. Jude Children’s Research Hospital, Memphis (TN), USA.
3. Department of Pediatrics, Division of Pediatric Epidemiology & Clinical Research, University of Minnesota, Minneapolis (MN), USA.
4. Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham (AL), USA.
5. Department of Mathematics, University of North Texas, Denton (TX), USA.
6. Department of Medicine, University of Tennessee, Memphis (TN), USA.
7. Department of Pharmacology, Northwestern University, Chicago (IL), USA.
8. Department of Medicine, Duke University School of Medicine, Durham (NC), USA.
9. Department of Pediatrics, Baylor College of Medicine, Houston (TX), USA.
10. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham (AL), USA.
11. Fred Hutchinson Cancer Center, Seattle Children’s Hospital, University of Washington, Seattle, (WA), USA.
Title: A genome-wide association study for doxorubicin-induced cardiomyopathy in childhood cancer survivors from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor (CCSS) Studies.

**Background:** Treatment of childhood cancer using doxorubicin is associated with a well-established dose-related risk of cardiomyopathy, which can lead to heart failure and affects ~7-10% of exposed children and adolescents. Here, we identified a genetic variant associated with risk of doxorubicin-induced cardiomyopathy (diCM) in survivors of childhood cancer.

**Methods:** A genome-wide association study using common variants (MAF≥5%; whole-genome sequencing data) was performed among 993 SJLIFE survivors of European ancestry (median age, 36.6 years; range, 8.7-62.2 years) treated with doxorubicin only (210 with diCM; defined as CTCAE grade ≥2 clinically assessed cardiomyopathy). Replication analyses were performed separately among 1,430 CCSS survivors of European ancestry (median age, 35.4 years; range, 15.8-60.7 years) and 159 SJLIFE survivors of African ancestry (median age, 32.6 years; range, 8.9-61.1 years) exposed to doxorubicin only. Analyses were adjusted for age at primary cancer diagnosis, sex, doxorubicin dose, age at last contact and top five principal components.

**Results:** We identified a genome-wide significant association between a novel locus near HS3ST4 and diCM risk in SJLIFE survivors of European ancestry (rs112474856; OR=2.78; P=3.3×10⁻⁸). This association replicated in CCSS survivors of European ancestry (OR=1.74, P=0.036) but had an opposite effect among SJLIFE survivors of African ancestry (OR=0.34, P=0.028). SNP rs112474856 did not show significant association with diCM risk in two independent datasets including survivors of European ancestry in SJLIFE (OR=1.20; P=0.71) and CCSS (OR=1.02; P=0.98) who were not exposed to doxorubicin but were treated with daunorubicin or chest radiotherapy, suggesting doxorubicin specificity. No association was observed between rs112474856 and risks of cardiomyopathy (OR=1.00; P=0.88) or heart failure (OR=1.00; P=0.59) in 361,194 UK Biobank participants from the general population. HS3ST4 was significantly upregulated (P=4.7×10⁻⁶) in response to doxorubicin...
treatment in human induced pluripotent stem-cell-derived cardiomyocytes from patients with diCM. *HS3ST4* encodes heparan sulfate, the latter was recently linked to immune activation, cardiac fibrosis, and heart failure.

**Conclusions:** Leveraging the two largest cohorts of childhood cancer survivors in North America, we identified and replicated a novel locus for diCM which was associated with increased risk in survivors of European ancestry but decreased in their African counterpart.